The efficacy of different regimens in the salvage therapy of elderly patients with refractory diffuse large B-cell lymphoma
10.3760/cma.j.issn.0254-9026.2013.02.018
- VernacularTitle:老年人难治弥漫大B细胞淋巴瘤不同挽救方案疗效分析
- Author:
Jie SHI
;
Kai SUN
;
Yin ZHANG
;
Yuqing CHEN
;
Pingchong LEI
;
Yuzhu ZANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,B-cell;
Salvage therapy;
Antineoplastic combined chemotherapy protocols
- From:
Chinese Journal of Geriatrics
2013;(2):184-187
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and toxicities of gemcitabine plus oxaliplatin with R-GemOx or without (GemOx) rituximab regimen in the treatment of relapsed or refractory diffuse large B-cell lymphoma in elderly patients.Methods A total of 39 patients with relapsed or refractory diffuse large B-cell lymphoma received R-GemOx or GemOx chemotherapy.There were 16 patients in R-GemOx and 23 patients in GemOx group.Patients in both groups received gemcitabine 1000 mg/m2,d1,at land 8 day and oxaliplatin 130 mg/m2,d1 at lday.Patients in R-GemOx additionally received rituximab 375 mg/m2.Every 21-28 days was 1 cycle.The toxicities were evaluated after 1 cycle of chemotherapy.The efficacy was evaluated after 2 cycles of chemotherapy.Results In R-GemOx group,the total response rate was 62.5％,and the clinical benefit rate was 87.5％.In GemOx group,the total response rate was 47.8％,and the clinical benefit rate was 73.9％ There was no significant differences between the two groups.There was a significant difference in the median time-to-progression (TTP) between R-GemOx group (6.4 months) and GemOx group (5.0 months) (P ＜ 0.05).The major toxicities were marrow suppression and gastrointestinal reaction,which had no significant differences between the two groups.Conclusions R-GemOx and GemOx regimen are effective and safe for the elderly patients with relapsed or refractory diffuse large B-cell lymphoma(DLBCL).But the patients with relapsed/refractory DLBCL treated with R-GemOx had a longer median time-to-progression than with GemOx regimen.
